This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Pardes Biosciences Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Pardes Biosciences.
Wichtige Informationen
36.6%
Wachstumsrate der Gewinne
39.3%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 24.7% |
| Wachstumsrate der Einnahmen | n/a |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 17 Jul 2023 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate
Jul 18
Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation
Jan 20We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully
Oct 01Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19
Sep 13Pardes Biosciences GAAP EPS of -$0.48
Aug 15Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans
Jun 14Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform
Jan 21Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2025 | N/A | -34 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -33 | N/A | N/A | 1 |
| 12/31/2023 | N/A | -77 | N/A | N/A | 1 |
| 6/30/2023 | N/A | -76 | -79 | -79 | N/A |
| 3/31/2023 | N/A | -93 | -78 | -78 | N/A |
| 12/31/2022 | N/A | -97 | -72 | -72 | N/A |
| 9/30/2022 | N/A | -87 | -76 | -76 | N/A |
| 6/30/2022 | N/A | -75 | -67 | -67 | N/A |
| 3/31/2022 | N/A | -55 | -54 | -54 | N/A |
| 12/31/2021 | N/A | -39 | -37 | -37 | N/A |
| 9/30/2021 | N/A | -36 | -23 | -23 | N/A |
| 6/30/2021 | N/A | -27 | -14 | -14 | N/A |
| 3/31/2021 | N/A | -20 | -8 | -8 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: PRDS is forecast to remain unprofitable over the next 3 years.
Ertrag vs. Markt: PRDS is forecast to remain unprofitable over the next 3 years.
Hohe Wachstumserträge: PRDS is forecast to remain unprofitable over the next 3 years.
Einnahmen vs. Markt: Insufficient data to determine if PRDS's revenue is forecast to grow faster than the US market.
Hohe Wachstumseinnahmen: PRDS is forecast to have no revenue next year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Insufficient data to determine if PRDS's Return on Equity is forecast to be high in 3 years time